From November 16th to 17th, 2024, the First International Summit on Cross-Innovation and High-Quality Development of Nanobodies was held in Nanning, Guangxi, China. This academic event brought together experts and scholars from around the world to discuss the latest research findings, technological innovations, and future trends in nanobodies and related cross-innovation areas.

At this event, Yaohai Bio-Pharma's innovative technological achievements in nanobody CRDMO (Contract Research, Development, and Manufacturing Organization) services were a major focus. It was also a great honor to welcome Professor Serge Muyldermans, the discoverer of the presence of the unique heavy chain-only antibodies (HCAbs) in camelids and a professor at the Vrije Universiteit Brussel in Belgium, to the Yaohai Bio-Pharma exhibition stand for academic exchanges and guidance. As one of the most influential scholars in the global nanobody field, Professor Serge Muyldermans has been researching nanobodies for nearly 40 years. He is also a co-founder of Ablynx, a leading international nanobody company acquired by Sanofi for 3.9 billion euros in 2018. He has made outstanding contributions to the global scientific research and clinical application of nanobody technology.

During the conversation, Professor Serge Muyldermans inquired in detail about Yaohai Bio-Pharma's latest technological achievements in nanobody research and biotechnology services. While providing guidance, he also generously shared his valuable experience in nanobody research. Professor Serge Muyldermans' experience sharing provided Yaohai Bio-Pharma with higher-level and more cutting-edge insights and information. This was not only a recognition of Yaohai Bio-Pharma's past efforts but also further strengthened the company's determination to continue innovating and developing in the field of nanobodies.

As a globally leading CRDMO service provider in microbial expression systems, Yaohai Bio-Pharma boasts extensive experience in nanobody research and production. Relying on its mature and comprehensive microbial synthetic expression platform, strong production capacity, and strict quality management system, Yaohai Bio-Pharma's nanobody CRDMO platform has successfully delivered multiple nanobody projects. Its scaled-up production capacity provides a solid guarantee for the high yield, efficiency, and quality requirements of nanobody projects.

In the future, Yaohai Bio-Pharma will continue to deepen its research in nanobody technology, continually enhance its service capabilities, and strive to provide more efficient, one-stop solutions for our global partners. Together, we will promote the advancement of nanobody technology and bring more treatment options and hope to patients worldwide.

We are also actively seeking institutional or individual global partners. We offer the most competitive compensation in the industry. If you have any questions, please feel free to contact us at [email protected]